Article

Estrogen, estrogen plus progestin therapy, and risk of breast cancer.

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115. USA.
Clinical Cancer Research (Impact Factor: 8.19). 02/2005; 11(2 Pt 2):909s-17s.
Source: PubMed

ABSTRACT Epidemiologic evidence relating use of postmenopausal hormones to risk of breast cancer by nature relies on trends in prescribing practices. Data on the adverse effect of combination estrogen plus progestin used for long durations has only become available over the past decade. Evidence is reviewed relating estrogen alone and estrogen plus progestin to increased risk of breast cancer. Whereas current evidence indicates that longer duration of use increases risk of invasive breast cancer regardless of formulation, the rate of increase in risk is greater for combination estrogen plus progestin therapy. Although data are limited, continuous combined therapy and sequential therapy seem to have comparable impact on breast cancer risk. Combination therapy is more strongly related to lobular breast cancer than is estrogen alone. Unresolved issues remain about dose of estrogen and progestin in relation to risk, and about identification of women for whom short-term use to relieve menopausal symptoms may be safe and effective.

0 Bookmarks
 · 
20 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Often viewed as the definitive professional document on transgender care, the current Standards of Care for Gender Identity Disorders—Sixth Version provides a general overview of the risks and effects of adult hormone therapy, but at present offers limited guidance for the medical provider as to how best to execute this critical intervention. Newer versions need to present a comprehensive approach to transgender hormone therapy, including preventive health care, by incorporating the following key elements: the prescribing physician's responsibilities, clinical situations for hormone therapy, effects and risks of hormone therapy, assessment for initiating hormone therapy, monitoring hormone therapy, and suggested hormone regimens.
    International Journal of Transgenderism 08/2009; 11(3):146-182. DOI:10.1080/15532730903383757
  • [Show abstract] [Hide abstract]
    ABSTRACT: Menopausal hormone therapy with estrogen plus progestin or estrogen alone (for women with prior hysterectomy) is still used by millions of women for climacteric symptom management throughout the world. Until 2002, hormone therapy influence on cancer risk and other chronic diseases was determined through observational study reports. Since then, results from the Women's Health Initiative randomized, placebo-controlled hormone therapy trials have substantially changed concepts regarding estrogen plus progestin and estrogen alone influence on the most common cancers in postmenopausal women. In these trials, estrogen plus progestin significantly increased breast cancer incidence and deaths from breast cancer, significantly increased deaths from lung cancer, significantly decreased endometrial cancer, and did not have a clinically significant influence on colorectal cancer. In contrast, estrogen alone use in women with prior hysterectomy significantly reduced breast cancer incidence and deaths from breast cancer without significant influence on colorectal cancer or lung cancer. These complex results are discussed in the context of known potential mediating mechanisms of action involved in interactionwith steroid hormone receptors.
    Steroids 06/2014; DOI:10.1016/j.steroids.2014.06.001 · 2.72 Impact Factor
  • Source